Wednesday - January 22, 2025
SAN FRANCISCO, March 02, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health company focused on creating trusted solutions that detect, predict, and prevent disease, will have the results of four studies presented by leading clinical investigators at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC) from March 4-6, 2023, in New Orleans, LA.
These studies further strengthen iRhythm’s body of clinical and scientific evidence to differentiate its Zio suite of products and services. New research will include data from the CAMELOT study, the first and largest study of its kind1,2 to evaluate diagnostic yield, time to clinical diagnosis, retest rates, and healthcare resource utilization among different cardiac monitoring services, and will also detail initial clinical experience with the next generation of iRhythm’s ECG patch, the Zio monitor, which will be commercially available later this year.
Clinical findings will be presented at the conference during the times listed below.
Saturday, Mar. 4
Sunday, Mar. 5
Monday, Mar. 6
To join iRhythm at ACC.23/WCC, please visit booth #129 to learn more. Clinicians and health care professionals can also RSVP for an educational event, “Cardiac Monitoring: Clinical Challenges, Evidence Gaps, and Patient Outcomes,” here.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
1 Reynolds et al. Comparative Effectiveness Of Ambulatory Monitors For Arrhythmia Diagnosis: A retrospective analysis of Medicare beneficiaries managed with ambulatory cardiac monitors between 2017 and 2019. Accepted for ACC.23 presentation, presented in New Orleans, LA.
2 Data on file. iRhythm Technologies, 2023.
Investor Relations Contact:
Stephanie Zhadkevich
(919) 452-5430
investors@irhythmtech.com
iRhythm Media Contact:
Morgan Mathis
(310) 528-6306
irhythm@highwirepr.com
Last Trade: | US$108.71 |
Daily Change: | 0.38 0.35 |
Daily Volume: | 243,744 |
Market Cap: | US$3.400B |
December 30, 2024 October 30, 2024 October 30, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load